Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close. We recently published a list of the 11 Best Pharma Stocks to Buy ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

After hours: March 14 at 7:55:29 PM EDT Loading Chart for VRTX ...

Vertex Pharmaceuticals EVP Ourania Tatsis sold 3,242 shares worth $1.62 million under a pre-arranged plan. The sale, executed on March 10, 2025, priced each share at $499.99, with Tatsis still holding ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 5 years by 2.37% on an annualized basis producing an average annual return of 19.23%. Currently, Vertex Pharmaceuticals has a ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Other Print Features Collate, 360 Nozzles Black, Bi-directional and Uni-directional Printing, 3 pl Minimum Ink Droplet Volume, 15 ipm Print Speed for ISO Default - ISO 24724 Black, PC Printing/PGPP ...

MercadoLibre Inc. $2,072.75 51.38 2.54% ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...